GT200900019AA - PEPTIDOMIMETICS OF SMAC USEFUL AS INHIBITORS OF APOPTOSIS PROTEINS (AIP) - Google Patents
PEPTIDOMIMETICS OF SMAC USEFUL AS INHIBITORS OF APOPTOSIS PROTEINS (AIP)Info
- Publication number
- GT200900019AA GT200900019AA GT200900019AK GT200900019K GT200900019AA GT 200900019A A GT200900019A A GT 200900019AA GT 200900019A K GT200900019A K GT 200900019AK GT 200900019 K GT200900019 K GT 200900019K GT 200900019A A GT200900019A A GT 200900019AA
- Authority
- GT
- Guatemala
- Prior art keywords
- smac
- aip
- peptidomimetics
- inhibitors
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
Abstract
LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA A UN COMPUESTO DE LA FÓRMULA (I)O SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS Y EL USO DE TALES COMPUESTOS PARA EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS TALES COMO CÁNCER, EN MAMÍFEROS.THIS INVENTION IS DIRECTED TO A COMPOSITE OF FORMULA (I) OR PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME AND THE USE OF SUCH COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER, IN MAMMALS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83500006P | 2006-08-02 | 2006-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200900019AA true GT200900019AA (en) | 2015-11-24 |
Family
ID=38686647
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200900019A GT200900019A (en) | 2006-08-02 | 2009-01-30 | ORGANIC COMPOUNDS |
GT200900019AK GT200900019AA (en) | 2006-08-02 | 2013-10-23 | PEPTIDOMIMETICS OF SMAC USEFUL AS INHIBITORS OF APOPTOSIS PROTEINS (AIP) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200900019A GT200900019A (en) | 2006-08-02 | 2009-01-30 | ORGANIC COMPOUNDS |
Country Status (42)
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2253614T3 (en) | 2004-04-07 | 2013-01-07 | Novartis Ag | IAP inhibitors |
AU2005274937B2 (en) | 2004-07-15 | 2011-08-18 | Medivir Ab | IAP binding compounds |
EP1836201B2 (en) | 2004-12-20 | 2013-09-04 | Genentech, Inc. | Pyrrolidine inhibitors of iap |
EP1851200B1 (en) | 2005-02-25 | 2014-01-15 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2006122408A1 (en) | 2005-05-18 | 2006-11-23 | Aegera Therapeutics Inc. | Bir domain binding compounds |
JP2009512719A (en) | 2005-10-25 | 2009-03-26 | アエゲラ セラピューティクス インコーポレイテッド | IAPBIR domain binding compound |
TWI504597B (en) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | Iap bir domain binding compounds |
US8163792B2 (en) | 2006-05-16 | 2012-04-24 | Pharmascience Inc. | IAP BIR domain binding compounds |
JP5452223B2 (en) | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | IAP inhibitor |
WO2008014236A1 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
BRPI0715195A2 (en) | 2006-07-24 | 2013-06-11 | Tetralogic Pharm Corp | compound, methods for inducing and stimulating apoptosis in a cell, for enhancing apoptosis of pathogenic cells in vivo in an individual, and for treating a disease, and, pharmaceutical composition. |
KR20090082221A (en) * | 2006-10-19 | 2009-07-29 | 노파르티스 아게 | Organic Compounds |
CN101541325A (en) * | 2006-11-28 | 2009-09-23 | 诺瓦提斯公司 | Use of IAP inhibitors for the treatment of acute myeloid leukemia |
ATE509629T1 (en) * | 2006-11-28 | 2011-06-15 | Novartis Ag | COMBINATION OF IAP INHIBITORS AND FLT3 INHIBITORS |
KR20090094461A (en) * | 2006-12-19 | 2009-09-07 | 제넨테크, 인크. | Imidazopyridine inhibitors of iap |
MX2009011783A (en) | 2007-04-30 | 2009-12-04 | Genentech Inc | Inhibitors of iap. |
KR20110022608A (en) * | 2008-05-16 | 2011-03-07 | 노파르티스 아게 | Immunomodulation by iap inhibitors |
NZ590550A (en) | 2008-08-02 | 2013-05-31 | Genentech Inc | Inhibitors of Apoptosis (IAP) for treating cancer |
US8841067B2 (en) | 2009-01-09 | 2014-09-23 | Dana-Farber Cancer Institute, Inc. | NOL3 is a predictor of patient outcome |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
TW201109335A (en) | 2009-08-04 | 2011-03-16 | Takeda Pharmaceutical | Heterocyclic compounds |
EP2464347A1 (en) * | 2009-08-11 | 2012-06-20 | Novartis AG | Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists |
KR20180020315A (en) * | 2009-08-12 | 2018-02-27 | 노파르티스 아게 | Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein |
ES2625637T3 (en) | 2010-02-12 | 2017-07-20 | Pharmascience Inc. | BIR IAP domain binding compounds |
UY33236A (en) | 2010-02-25 | 2011-09-30 | Novartis Ag | DIMERIC INHIBITORS OF THE IAP |
DK2611797T3 (en) * | 2010-08-31 | 2017-02-13 | Hanmi Science Co Ltd | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSE-INducing ACTIVITY ON CELLS |
WO2012052758A1 (en) | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
UY33794A (en) | 2010-12-13 | 2012-07-31 | Novartis Ag | DIMERIC INHIBITORS OF THE IAP |
WO2013012723A1 (en) | 2011-07-13 | 2013-01-24 | Novartis Ag | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
US9227982B2 (en) | 2011-07-13 | 2016-01-05 | Novartis Ag | 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors |
CA2850330A1 (en) | 2011-09-30 | 2013-04-04 | Tetralogic Pharmaceuticals Corporation | Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer) |
US8859541B2 (en) * | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
EP2852584B1 (en) * | 2012-05-22 | 2018-02-28 | F. Hoffmann-La Roche AG | Substituted dipyridylamines and uses thereof |
KR20140011773A (en) * | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | Heterocyclic derivatives with dual inhibitory activity |
CN105164114B (en) | 2013-05-01 | 2018-03-23 | 豪夫迈·罗氏有限公司 | The miazines and their purposes of the Heterocyclylalkyl substitution of C connections |
ES2828642T3 (en) | 2013-06-25 | 2021-05-27 | Walter & Eliza Hall Inst Medical Res | Smac mimics for the treatment of persistent intracellular HBV infection |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
CN106103484B (en) | 2014-03-14 | 2021-08-20 | 诺华股份有限公司 | Antibody molecules against LAG-3 and uses thereof |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
KR20170066546A (en) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | Combination therapies |
MA41044A (en) | 2014-10-08 | 2017-08-15 | Novartis Ag | COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT |
CU20170052A7 (en) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | ANTIBODY MOLECULES THAT JOIN PD-L1 |
WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
SI3317301T1 (en) | 2015-07-29 | 2021-10-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
BR112018008904A2 (en) | 2015-11-03 | 2018-11-27 | Janssen Biotech Inc | antibodies specifically binding to tim-3 and their uses |
CA3007671A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
JP2019514878A (en) | 2016-04-20 | 2019-06-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Conjugates Comprising RIPK2 Inhibitors |
GB201610147D0 (en) | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
CN106496213B (en) * | 2016-09-30 | 2019-08-20 | 东南大学 | LCL161 prodrug and its preparation method and application |
JP6899993B2 (en) * | 2016-10-04 | 2021-07-07 | 国立医薬品食品衛生研究所長 | Heterocyclic compound |
CN110475567A (en) | 2017-03-31 | 2019-11-19 | 勃林格殷格翰国际有限公司 | Anticancer combination therapy |
UY37695A (en) | 2017-04-28 | 2018-11-30 | Novartis Ag | BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME |
JP7433910B2 (en) | 2017-06-22 | 2024-02-20 | ノバルティス アーゲー | Antibody molecules against CD73 and uses thereof |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
JP2021503478A (en) | 2017-11-16 | 2021-02-12 | ノバルティス アーゲー | Combination treatment |
CN108484640B (en) * | 2018-05-22 | 2020-09-15 | 南京华威医药科技集团有限公司 | Anti-tumor apoptosis protein inhibitor |
TW202015726A (en) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
TW202016151A (en) | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | Multi-specific binding proteins for cancer treatment |
JPWO2020027225A1 (en) | 2018-07-31 | 2021-11-11 | ファイメクス株式会社 | Heterocyclic compound |
WO2020148447A1 (en) | 2019-01-17 | 2020-07-23 | Debiopharm International S.A. | Combination product for the treatment of cancer |
TW202043466A (en) | 2019-01-25 | 2020-12-01 | 德商百靈佳殷格翰國際股份有限公司 | Recombinant rhabdovirus encoding for ccl21 |
JP2022532918A (en) | 2019-05-20 | 2022-07-20 | ノバルティス アーゲー | MCL-1 Inhibitor Antibody-Drug Conjugate and Usage |
JPWO2021020585A1 (en) | 2019-07-31 | 2021-02-04 | ||
JP2022548881A (en) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy |
MX2022003628A (en) | 2019-09-25 | 2022-07-21 | Debiopharm Int Sa | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma. |
CA3166980A1 (en) | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
CN115916231A (en) | 2020-06-03 | 2023-04-04 | 勃林格殷格翰国际有限公司 | Recombinant rhabdovirus encoding CD80 ectodomain Fc fusion protein |
EP4251648A2 (en) | 2020-11-24 | 2023-10-04 | Novartis AG | Anti-cd48 antibodies, antibody drug conjugates, and uses thereof |
JP2023553808A (en) | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | MCL-1 inhibitor antibody-drug conjugates and methods of use |
WO2022169780A1 (en) | 2021-02-02 | 2022-08-11 | Les Laboratoires Servier | Selective bcl-xl protac compounds and methods of use |
WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2714880A1 (en) | 1977-04-02 | 1978-10-26 | Hoechst Ag | CEPHEMDER DERIVATIVES AND PROCESS FOR THEIR PRODUCTION |
JPS59141547A (en) | 1983-02-01 | 1984-08-14 | Eisai Co Ltd | Novel peptide having analgesic action and its preparation |
FR2575753B1 (en) | 1985-01-07 | 1987-02-20 | Adir | NOVEL PEPTIDE DERIVATIVES WITH NITROGEN POLYCYCLIC STRUCTURE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
DK167813B1 (en) | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | PENTAPEPTIDE DERIVATIVES, PHARMACEUTICAL ACCEPTABLE SALTS, PROCEDURES FOR PREPARING IT AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH DERIVATIVE |
US5559209A (en) | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
US6472172B1 (en) | 1998-07-31 | 2002-10-29 | Schering Aktiengesellschaft | DNA encoding a novel human inhibitor-of-apoptosis protein |
MXPA02000823A (en) | 2000-05-23 | 2002-07-30 | Vertex Pharma | Caspase inhibitors and uses thereof. |
US6608026B1 (en) | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
US20020160975A1 (en) | 2001-02-08 | 2002-10-31 | Thomas Jefferson University | Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis |
WO2003040172A2 (en) | 2001-11-09 | 2003-05-15 | Aegera Therapeutics, Inc. | Methods and reagents for peptide-bir interaction screens |
JP4541882B2 (en) | 2002-07-02 | 2010-09-08 | ノバルティス アーゲー | Peptide inhibitor for binding of SMAC protein to apoptotic protein inhibitor (IAP) |
DE60324964D1 (en) | 2002-07-15 | 2009-01-08 | Univ Princeton | IAP-BINDING CONNECTIONS |
US20040171554A1 (en) | 2003-02-07 | 2004-09-02 | Genentech, Inc. | Compositions and methods for enhancing apoptosis |
CA2543897A1 (en) | 2003-11-13 | 2005-06-02 | Genentech, Inc. | Compositions and methods for screening pro-apoptotic compounds |
JP2007523061A (en) * | 2004-01-16 | 2007-08-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | SMAC peptide mimetics and uses thereof |
SE527038C2 (en) * | 2004-02-26 | 2005-12-13 | Ingenjoers N Per Oskar Persson | Cassette and liquid freezing apparatus |
JP4674231B2 (en) * | 2004-03-01 | 2011-04-20 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Dimer small molecule apoptosis enhancer |
DK2253614T3 (en) * | 2004-04-07 | 2013-01-07 | Novartis Ag | IAP inhibitors |
CN101035802A (en) | 2004-07-02 | 2007-09-12 | 健泰科生物技术公司 | Inhibitors of IAP |
EP1836201B2 (en) | 2004-12-20 | 2013-09-04 | Genentech, Inc. | Pyrrolidine inhibitors of iap |
US20060218632A1 (en) * | 2005-03-28 | 2006-09-28 | Cisco Technology, Inc.; | Method and system for installing premise equipment |
AU2007307763A1 (en) * | 2006-10-12 | 2008-04-17 | Novartis Ag | Pyrrolydine derivatives as IAP inhibitors |
MX2009005934A (en) * | 2006-12-07 | 2009-06-17 | Novartis Ag | Organic compounds. |
-
2007
- 2007-07-26 PE PE2011000114A patent/PE20110224A1/en active IP Right Grant
- 2007-07-26 PE PE2011000112A patent/PE20110218A1/en not_active Application Discontinuation
- 2007-07-26 PE PE2007000978A patent/PE20080951A1/en active IP Right Grant
- 2007-07-26 PE PE2011000113A patent/PE20110220A1/en not_active Application Discontinuation
- 2007-07-26 PE PE2011000111A patent/PE20110217A1/en not_active Application Discontinuation
- 2007-07-31 PT PT78135696T patent/PT2051990E/en unknown
- 2007-07-31 EP EP12184700A patent/EP2537850A1/en not_active Withdrawn
- 2007-07-31 EP EP07813569A patent/EP2051990B1/en active Active
- 2007-07-31 WO PCT/US2007/074790 patent/WO2008016893A1/en active Application Filing
- 2007-07-31 KR KR1020097004264A patent/KR101087878B1/en active IP Right Grant
- 2007-07-31 AR ARP070103375A patent/AR062159A1/en not_active Application Discontinuation
- 2007-07-31 EP EP12184747.9A patent/EP2537846B1/en active Active
- 2007-07-31 CN CN201110446951.8A patent/CN102558165B/en active Active
- 2007-07-31 CA CA2658525A patent/CA2658525C/en active Active
- 2007-07-31 ES ES12184747.9T patent/ES2559042T3/en active Active
- 2007-07-31 PL PL07813569T patent/PL2051990T3/en unknown
- 2007-07-31 DK DK07813569.6T patent/DK2051990T3/en active
- 2007-07-31 MX MX2009001212A patent/MX2009001212A/en active IP Right Grant
- 2007-07-31 SI SI200731218T patent/SI2051990T1/en unknown
- 2007-07-31 CN CN2007800329568A patent/CN101511860B/en active Active
- 2007-07-31 AU AU2007281230A patent/AU2007281230B2/en active Active
- 2007-07-31 GE GEAP200711084A patent/GEP20115251B/en unknown
- 2007-07-31 NZ NZ574393A patent/NZ574393A/en not_active IP Right Cessation
- 2007-07-31 UA UAA200900768A patent/UA95485C2/en unknown
- 2007-07-31 EA EA200900227A patent/EA021671B1/en not_active IP Right Cessation
- 2007-07-31 US US12/376,057 patent/US8552003B2/en active Active
- 2007-07-31 JP JP2009523001A patent/JP4875749B2/en active Active
- 2007-07-31 BR BRPI0714803A patent/BRPI0714803B8/en active IP Right Grant
- 2007-07-31 KR KR1020117002855A patent/KR101245945B1/en active IP Right Grant
- 2007-07-31 MY MYPI20090334 patent/MY150460A/en unknown
- 2007-07-31 ME MEP-2009-19A patent/ME00585B/en unknown
- 2007-07-31 EA EA201401247A patent/EA201401247A1/en unknown
- 2007-07-31 ES ES07813569T patent/ES2405947T3/en active Active
- 2007-08-01 TW TW096128289A patent/TWI408133B/en not_active IP Right Cessation
- 2007-08-01 CL CL200702234A patent/CL2007002234A1/en unknown
- 2007-08-02 JO JO2007318A patent/JO2848B1/en active
- 2007-08-02 PA PA20078740901A patent/PA8740901A1/en unknown
-
2009
- 2009-01-16 ZA ZA2009/00371A patent/ZA200900371B/en unknown
- 2009-01-16 CR CR10567A patent/CR10567A/en unknown
- 2009-01-19 IL IL196596A patent/IL196596A/en active IP Right Grant
- 2009-01-22 NI NI200900008A patent/NI200900008A/en unknown
- 2009-01-22 NI NI2009000081A patent/NI200900081A/en unknown
- 2009-01-29 CU CU20090017A patent/CU23866B1/en active IP Right Grant
- 2009-01-30 GT GT200900019A patent/GT200900019A/en unknown
- 2009-01-30 HN HN2009000214A patent/HN2009000214A/en unknown
- 2009-01-30 TN TN2009000034A patent/TN2009000034A1/en unknown
- 2009-02-02 SV SV2009003160A patent/SV2009003160A/en active IP Right Grant
- 2009-02-17 MA MA31648A patent/MA30652B1/en unknown
- 2009-02-25 NO NO20090878A patent/NO342230B1/en not_active IP Right Cessation
- 2009-02-26 SM SM200900013T patent/SMP200900013B/en unknown
- 2009-07-22 HK HK09106712.5A patent/HK1127616A1/en not_active IP Right Cessation
- 2009-07-22 HK HK13103786.7A patent/HK1176613A1/en not_active IP Right Cessation
-
2011
- 2011-02-02 CU CU2011000027A patent/CU24004B1/en active IP Right Grant
-
2012
- 2012-09-07 US US13/606,676 patent/US8546336B2/en active Active
-
2013
- 2013-04-16 DO DO2013000084A patent/DOP2013000084A/en unknown
- 2013-04-29 HR HRP20130373TT patent/HRP20130373T1/en unknown
- 2013-08-29 US US14/013,666 patent/US20140004101A1/en not_active Abandoned
- 2013-10-23 GT GT200900019AK patent/GT200900019AA/en unknown
-
2014
- 2014-02-20 IL IL231079A patent/IL231079A/en active IP Right Grant
- 2014-12-03 CR CR20140555A patent/CR20140555A/en unknown
-
2015
- 2015-01-22 IL IL236883A patent/IL236883A0/en unknown
-
2017
- 2017-12-04 AR ARP170103398A patent/AR110313A2/en unknown
-
2018
- 2018-09-17 AR ARP180102641A patent/AR112816A2/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200900019AA (en) | PEPTIDOMIMETICS OF SMAC USEFUL AS INHIBITORS OF APOPTOSIS PROTEINS (AIP) | |
BRPI0815708A8 (en) | benzylbenzene-derived compound as sglt inhibitor, pharmaceutical composition, and use of a compound | |
GT201100181A (en) | "PROTEIN CINASE INHIBITORS" | |
CL2012001911A1 (en) | Compounds derived from fumarate; pharmaceutical composition comprising them; and its use in the treatment of an inflammatory or neurodegenerative disease. | |
ECSP12012318A (en) | PIRAZOLIL QUINAZOLINA CINASA INHIBITORS | |
CO6771447A2 (en) | Cyclopropylamines as lysine specific demethylase 1 inhibitors | |
CL2007002166A1 (en) | Compounds derived from nitrogen heterocycles, antagonists of apoptosis protein inhibitors; its pharmaceutical compositions; and use of said compounds for the treatment of cancer. | |
CL2008002430A1 (en) | Benzenesulfonamide derived compounds, cathepsin c inhibitors; pharmaceutical composition comprising them; and its use for the treatment of copd. | |
ECSP099445A (en) | QUINAZOLINS FOR THE INHIBITION OF PDK1 | |
CL2008003690A1 (en) | Compounds derived from ammonobenzamide; pharmaceutical composition comprising the compounds; and use to control parasites. | |
CR11684A (en) | REPLACED DIHYDROPIRAZOLONES OF HIF-PROPIL-4- AS HYDROXYLASE INHIBITORS | |
UY32622A (en) | NEW COMPOUNDS FOR THE TREATMENT OF PATHOLOGIES RELATED TO AB (BETA) | |
SV2009003389A (en) | PIRIDO COMPOUNDS [2,3-D] PIRIMIDINA-7-ONA AS P13K-ALFA INHIBITORS FOR CANCER TREATMENT | |
GT200900192A (en) | IMIDAZOL DERIVATIVES AS PROTEIN INHIBITORS FOR THE USE OF CINESINE (EG-5) .- | |
DOP2009000200A (en) | DERIVATIVES OF 2-AMINO-5,7-DIHIDRO-6H-PIRROLO [3,4-D] PIMIRIDINE AS HSP-90 INHIBITORS TO TREAT CANCER | |
CL2011000258A1 (en) | Compounds derived from phenylamino-isonicotinamide; mek inhibitors; Pharmaceutical composition and use for the treatment of hyperproliferative diseases such as cancer and inflammation. | |
CL2011000168A1 (en) | Compounds derived from narcyclasin and pancratistatin; preparation procedure; pharmaceutical composition; pharmaceutical combination; and its use for the treatment of cancer. | |
SV2010003773A (en) | 7-SULFANILMETIL-, 7-SULFINILMETIL- AND 7-SULFONILMETILINDOLES REPLACED AND THE USE OF THE SAME | |
CL2011001850A1 (en) | Use of a substituted heterocyclic nitrogen compound for the treatment of cancers such as colon cancer or multiple myeloma; pharmaceutical composition comprising the compound. | |
AR075783A1 (en) | PEPTIDE FOR PROFILACTIC OR THERAPEUTIC TREATMENT OF SKIN TUMORS IN INITIAL STAGES | |
UY30514A1 (en) | ORGANIC COMPOUNDS | |
CU20110026A7 (en) | SMAC PEPTIDOMYMETICS USEFUL AS INHIBITORS OF APOPTOSIS PROTEINS (IAP) | |
CU20110024A7 (en) | SMAC PEPTIDOMYMETICS USEFUL AS INHIBITORS OF APOPTOSIS PROTEINS (IAP) | |
CU20110025A7 (en) | SMAC PEPTIDOMYMETICS USEFUL AS INHIBITORS OF APOPTOSIS PROTEINS (IAP) | |
NI201200162A (en) | PIRAZOLIL QUINOXALINE KINASE INHIBITORS |